Keywords: tysabri, patients, remain, free, ms, years, five

Tysabri patients remain free of MS for two years

Article | 16 February 2009

Print This

Five times as many multiple sclerosis patients taking US biotechnology firm Biogen Idec and Ireland's Elan Corp's Tysabri (natalizumab) were ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in